data + articles · 1 listed
newest 2020spec sheet6 rows
Propentofylline was developed by the German pharmaceutical company Hoechst under the code HWA 285 as a glia-targeting approach to dementia, a methylxanthine derivative that inhibits adenosine reuptake and calms overactive microglia, on the theory that quieting neuroinflammation could slow neurodegeneration even without directly boosting neurotransmission. It advanced all the way to Phase III trials in Europe and North America during the 1990s for Alzheimer's disease and vascular dementia, and showed modest positive signals in some vascular-dementia cohorts, but it never delivered a clean enough efficacy result across trials to win broad approval and was ultimately discontinued, though it stayed available a while longer in a few markets such as Canada. It remains referenced in neuroinflammation research as one of the earlier serious attempts to treat dementia by targeting glial cells rather than neurons directly.
- reached Phase III trials for both Alzheimer's disease and vascular dementia
- showed modest positive signals in some vascular-dementia patient cohorts
- distinct glia-targeting, anti-neuroinflammatory mechanism versus most nootropics
- remained marketed in a few countries (e.g. Canada) after discontinuation elsewhere
- gastrointestinal side effects reported in some trial cohorts
- largely superseded in the research literature by amyloid- and tau-focused approaches
- Propentofylline reached full Phase III trials for both Alzheimer's disease and vascular dementia in the 1990s, further than most drugs in this archive ever get.
- It targeted microglia and neuroinflammation rather than neurons directly, an approach that has only become mainstream in Alzheimer's research decades later.
Mechanism
Non-selective phosphodiesterase inhibitor and ; suppresses microglial activation and associated pro-inflammatory release, and modestly improves cerebral blood flow and rheology.
Dosingtypical ranges, not medical advice
interested in protocols and clinical dosages? make an account to see them! ^_^
Safetyrisks and cautions, not medical advice
This one did not die on toxicity. Across Phase 1 to Phase 3 it was consistently described as well tolerated and free of severe side effects, with gastrointestinal upset the usual complaint and a food interaction significant enough that dosing had to be on an empty stomach an hour before meals. Aventis stopped development in 2000 after a 72-week Phase 3 failed to hold its benefit. Two caveats keep it honest: the Cochrane review found significantly more dropouts on propentofylline than placebo at twelve months, and the sponsor withheld data on roughly 1,200 further randomised patients.
History
Developed by Hoechst AG (Germany) as HWA 285; tested through Phase III trials in the 1990s for Alzheimer's disease and vascular dementia in Europe and North America; discontinued globally after failing to consistently meet regulatory efficacy bars, though it remained on some national markets, including Canada, for a period afterward.
Subjective profileweighing the evidence above
One of the first serious drugs to chase dementia through the glia instead of the neurons, a reasonable idea that just didn't clear a Phase III bar consistently enough to survive.
Resources
This entry is here for reference.
Research
1 listed here; entry last updated August 2026
Reviews
My notesprivate to this device
FAQ
Is propentofylline related to caffeine?
Yes, structurally; it is a methylxanthine derivative in the same broad chemical family as caffeine, theobromine and pentoxifylline, though its adenosine-reuptake-inhibiting and microglia-modulating profile is distinct from caffeine's adenosine-receptor-blocking action.
Why did it fail to reach approval everywhere?
Its Phase III results were inconsistent across trial sites and dementia subtypes; it showed modest benefit in some vascular dementia cohorts but not reliably enough overall to satisfy regulators broadly, leading to discontinuation in most markets.
Limitations of the evidence
- inconsistent efficacy across trials led to global discontinuation
Adverse effects
- gastrointestinal side effects reported in some trial cohorts
- largely superseded in the research literature by amyloid- and tau-focused approaches
Notes and cautions
- never approved in the US